UY33314A - Derivados de acido 1-amino-2-ciclopropiletilboronico - Google Patents

Derivados de acido 1-amino-2-ciclopropiletilboronico

Info

Publication number
UY33314A
UY33314A UY0001033314A UY33314A UY33314A UY 33314 A UY33314 A UY 33314A UY 0001033314 A UY0001033314 A UY 0001033314A UY 33314 A UY33314 A UY 33314A UY 33314 A UY33314 A UY 33314A
Authority
UY
Uruguay
Prior art keywords
cyclopropiletilboronic
amino
acid derivatives
compositions
compounds
Prior art date
Application number
UY0001033314A
Other languages
English (en)
Spanish (es)
Inventor
Li Jing
Paul E Fleming
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33314(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of UY33314A publication Critical patent/UY33314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
UY0001033314A 2010-03-31 2011-03-31 Derivados de acido 1-amino-2-ciclopropiletilboronico UY33314A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31

Publications (1)

Publication Number Publication Date
UY33314A true UY33314A (es) 2011-10-31

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033314A UY33314A (es) 2010-03-31 2011-03-31 Derivados de acido 1-amino-2-ciclopropiletilboronico

Country Status (26)

Country Link
US (3) US8513218B2 (https=)
EP (1) EP2552216B1 (https=)
JP (1) JP5933523B2 (https=)
KR (1) KR20130036228A (https=)
CN (3) CN102892291A (https=)
AR (1) AR080863A1 (https=)
AU (1) AU2011235227B2 (https=)
CA (1) CA2794334C (https=)
CL (1) CL2012002733A1 (https=)
CO (1) CO6630162A2 (https=)
CR (1) CR20120529A (https=)
DO (1) DOP2012000257A (https=)
EA (1) EA029521B1 (https=)
EC (1) ECSP12012249A (https=)
MA (1) MA34169B1 (https=)
MX (1) MX2012011298A (https=)
NZ (1) NZ602622A (https=)
PE (1) PE20130383A1 (https=)
PH (1) PH12012501943A1 (https=)
RU (1) RU2012146101A (https=)
SG (1) SG184222A1 (https=)
TN (1) TN2012000465A1 (https=)
UA (1) UA110612C2 (https=)
UY (1) UY33314A (https=)
WO (1) WO2011123502A1 (https=)
ZA (2) ZA201207406B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
RS60310B1 (sr) 2010-08-10 2020-07-31 Rempex Pharmaceuticals Inc Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
CN104126017A (zh) 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
SG11201403254QA (en) * 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN109180780B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US20160250238A1 (en) 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
SI3140310T1 (sl) 2014-05-05 2020-01-31 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli in njihova uporaba
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
EA201692301A1 (ru) * 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN107073069B (zh) 2014-08-18 2022-03-08 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
EP4606431A3 (en) 2017-02-28 2025-11-19 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
MX2020003495A (es) 2017-10-11 2020-09-18 Qpex Biopharma Inc Derivados de acido boronico y sintesis de los mismos.
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112022022367A2 (pt) 2020-05-05 2023-01-10 Qpex Biopharma Inc Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
WO2001064221A1 (en) 2000-02-29 2001-09-07 Bristol-Myers Squibb Co. Low dose entecavir formulation and use
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
ME01975B (me) 2004-03-30 2015-05-20 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
US7998997B2 (en) 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
PL2178888T3 (pl) 2007-08-06 2012-11-30 Millennium Pharm Inc Inhibitory proteasomów
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.

Also Published As

Publication number Publication date
AR080863A1 (es) 2012-05-16
NZ602622A (en) 2015-01-30
TN2012000465A1 (en) 2014-01-30
US20140179631A1 (en) 2014-06-26
PE20130383A1 (es) 2013-04-24
WO2011123502A1 (en) 2011-10-06
JP2013523760A (ja) 2013-06-17
CN102892291A (zh) 2013-01-23
CR20120529A (es) 2013-01-11
RU2012146101A (ru) 2014-05-10
EA201290980A1 (ru) 2013-03-29
SG184222A1 (en) 2012-10-30
MA34169B1 (fr) 2013-04-03
US8703743B2 (en) 2014-04-22
CA2794334A1 (en) 2011-10-06
US20110245203A1 (en) 2011-10-06
CL2012002733A1 (es) 2013-01-25
AU2011235227B2 (en) 2016-09-08
KR20130036228A (ko) 2013-04-11
JP5933523B2 (ja) 2016-06-08
EP2552216A4 (en) 2013-07-31
US9023832B2 (en) 2015-05-05
CN107266485A (zh) 2017-10-20
EA029521B1 (ru) 2018-04-30
ZA201207406B (en) 2014-01-29
CN106008570A (zh) 2016-10-12
US8513218B2 (en) 2013-08-20
UA110612C2 (uk) 2016-01-25
MX2012011298A (es) 2012-11-06
EP2552216A1 (en) 2013-02-06
CA2794334C (en) 2018-06-12
US20140011998A1 (en) 2014-01-09
ECSP12012249A (es) 2012-11-30
ZA201308086B (en) 2015-03-25
AU2011235227A1 (en) 2012-10-18
DOP2012000257A (es) 2012-11-15
CO6630162A2 (es) 2013-03-01
EP2552216B1 (en) 2018-01-24
PH12012501943A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
GT201400133A (es) Inhibidores de bromodominios
CR20160014A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
GT201300124A (es) Inhibidores de nampt y rock
ECSP10010015A (es) Inhibidores de proteasoma
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
PE20151023A1 (es) Triazolopirazinas
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
MX2019010602A (es) Inhibidores de cdk.
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR20140573A (es) Inhibidores del nampt
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20140553A (es) Compuestos de fenoxietil piperidina
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
UY34001A (es) Agentes para el control de la avispa de las agallas
CR20120134A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191218